Mammary tumors suppress aging-induced neuroinflammation in female Balb/c mice.
cancer
chemokines
cytokines
hippocampus
Journal
Comprehensive psychoneuroendocrinology
ISSN: 2666-4976
Titre abrégé: Compr Psychoneuroendocrinol
Pays: England
ID NLM: 101774169
Informations de publication
Date de publication:
Historique:
entrez:
29
7
2021
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
ppublish
Résumé
Neuroinflammation confers changes in brain function (i.e., behavior) that are hypothesized to be adaptive in the short-term, but detrimental (e.g., depression, anxiety) if they persist. Both peripheral tumor growth (outside of the brain) and natural aging independently cause neuroinflammation in rodents, which is corroborated by clinical studies. Mammary tumor effects on neuroinflammation and behavior, however, are typically studied in young rodents, whereas most breast cancer patients are middle-aged. Therefore, the existing literature likely underestimates the resulting neuroinflammation that may occur in clinical cancer populations. The present study tested the hypothesis that aging exacerbates mammary tumor-induced neuroinflammation in female mice. Aging (16 months and ovariectomized) increased body and spleen masses, whereas tumors grew faster and increased spleen mass in young mice (12 weeks) only. Tumors (IL-6, IL-10, Tnfα, MCP-1, CXCL1, IP-10) and aging (IL-10, IFNγ) independently increased circulating inflammatory markers, although these variables were only significantly additive in one case (TNFα). In contrast to our prediction, the interaction between tumors and aging resulted in reduced mRNA and protein expression of select inflammatory markers in the hippocampus of tumor-bearing aged mice relative to aged controls. These results indicate that tumors reduce inflammatory activation in the brains of aged mice, a deficit that is likely disadvantageous. Further understanding of how aging and cancer interact to affect brain function is necessary to provide clinically-relevant results and identify mechanisms underlying persistent behavioral issues hampering adult cancer patients.
Identifiants
pubmed: 34322676
doi: 10.1016/j.cpnec.2020.100002
pmc: PMC8315094
mid: NIHMS1652906
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIA NIH HHS
ID : R01 AG028271
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG058109
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG028271
Pays : United States
Références
Brain Behav Immun. 2019 Aug;80:805-817
pubmed: 31108169
Physiol Behav. 2012 Mar 20;105(5):1219-25
pubmed: 21549726
J Neurosci. 2005 Oct 5;25(40):9275-84
pubmed: 16207887
Recent Results Cancer Res. 1996;140:263-72
pubmed: 8787068
Neurobiol Aging. 2013 Dec;34(12):2748-58
pubmed: 23880139
Cancer Invest. 1997;15(5):416-21
pubmed: 9316623
Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):1106-15
pubmed: 17976923
Ann Oncol. 2001 Jul;12(7):997-1003
pubmed: 11521809
Behav Brain Res. 2017 Jul 14;330:108-117
pubmed: 28479263
Front Biosci. 2006 Jan 01;11:412-22
pubmed: 16146742
Brain Behav Immun. 2009 Mar;23(3):309-17
pubmed: 18814846
FASEB J. 2005 Aug;19(10):1329-31
pubmed: 15919760
Nat Rev Cancer. 2005 Aug;5(8):655-62
pubmed: 16056261
Physiol Behav. 2008 Feb 27;93(3):628-36
pubmed: 18068740
Neurobiol Aging. 2006 May;27(5):717-22
pubmed: 15890435
Brain Behav Immun. 2014 Feb;36:147-55
pubmed: 24513875
Biomed Pharmacother. 2017 Apr;88:698-707
pubmed: 28152479
Sci Rep. 2019 Jan 24;9(1):752
pubmed: 30679700
Physiol Behav. 2011 Sep 26;104(4):517-24
pubmed: 21530561
J Immunol. 2000 Mar 1;164(5):2619-28
pubmed: 10679101
Mech Ageing Dev. 2005 Dec;126(12):1305-13
pubmed: 16154177
Brain Behav Immun. 2012 Jul;26(5):766-77
pubmed: 22024136
Front Neuroendocrinol. 2012 Jan;33(1):105-15
pubmed: 22209870
J Neuroendocrinol. 2013 Nov;25(11):1095-103
pubmed: 23639063
Neurobiol Aging. 2017 Oct;58:88-101
pubmed: 28719855
J Natl Cancer Inst. 1964 Oct;33:649-56
pubmed: 14220248
Cell Immunol. 1982 Jan 15;66(2):372-82
pubmed: 6461422
Cancer Res. 1981 Feb;41(2):527-31
pubmed: 7448800
Hippocampus. 2003;13(7):826-34
pubmed: 14620878
Brain Behav Immun. 2015 Oct;49:1-17
pubmed: 25958011
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
J Inflamm (Lond). 2018 Nov 16;15:23
pubmed: 30473634
Vopr Onkol. 1981;27(8):52-9
pubmed: 7281593
J Neuroimmunol. 1999 Jan 1;93(1-2):139-48
pubmed: 10378877
Cancer Res. 1978 Oct;38(10):3174-81
pubmed: 210930
Neurobiol Aging. 2006 May;27(5):723-32
pubmed: 15893410
Brain Behav Immun. 2010 Oct;24(7):1190-201
pubmed: 20570721
Brain Behav Immun. 2004 Sep;18(5):407-13
pubmed: 15265532
Sci Rep. 2019 Apr 24;9(1):6497
pubmed: 31019214
Biol Psychiatry. 2009 Feb 15;65(4):304-12
pubmed: 18801476
Exp Biol Med (Maywood). 2004 Jul;229(7):665-75
pubmed: 15229361
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9069-74
pubmed: 19451634
Physiol Rep. 2019 Feb;7(3):e13995
pubmed: 30706674
Neurobiol Aging. 2016 Aug;44:22-41
pubmed: 27318131
J Psychiatr Res. 2016 Jan;72:43-50
pubmed: 26540403
J Neurosci. 2012 Oct 17;32(42):14641-8
pubmed: 23077050
Brain Behav Immun. 2010 Mar;24(3):502-11
pubmed: 20035859
Neuroscience. 2015 Nov 19;309:84-99
pubmed: 25772789
Brain Res. 2014 Mar 13;1552:55-63
pubmed: 24457042
Neuropsychopharmacology. 2015 Mar 13;40(5):1234-42
pubmed: 25409594
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
J Alzheimers Dis. 2017;58(3):829-840
pubmed: 28505968
Brain Behav Immun. 2014 Feb;36:111-7
pubmed: 24513871
Brain Behav Immun. 2010 Aug;24(6):903-7
pubmed: 20188817
Brain Behav Immun. 2009 Mar;23(3):396-401
pubmed: 19152833
Brain Behav Immun. 2015 Jan;43:76-85
pubmed: 25102452
Curr Opin Pharmacol. 2016 Feb;26:96-101
pubmed: 26595306